Mucin-Based Biotherapies for Pseudomonas aeruginosa Lung Infection
Technical Report,15 Feb 2019,14 Feb 2020
University of Maryland, Baltimore Campus Baltimore United States
Pagination or Media Count:
The purpose of this project is to demonstrate that MUC1 synthetic peptides will protect against Pseudomonas aeruginosa lung infection using both in vitro and in vivo model systems. For months 1-12 of the project, studies were conducted demonstrating that MUC1 20-,40-, 60-, 80-, and 100-mer peptides 1 bound to P. aeruginosa bacteria and its flagella, 2 competitively inhibited P. aeruginosa and its flagella binding to human lung cells, and flagella-dependent bacterial motility 3 were not cytotoxic to lung cells, 4 did not affect lung cell barrier formation, 5 exhibited no damage to mouse lung, liver or kidney when administered in vivo, and 6 displayed appropriate lung bioavailability in vivo. P. aeruginosa laboratory and clinical strains were tested. In all of the assays performed, the MUC1 peptides exhibited a relative potency according to the rank order 100-mer 80-mer 60-mer 40-mer 20-mer. These studies, and those to be performed in months 13-18 of the project, will provide preclinical data for future human clinical trials.
- Medicine and Medical Research